SWOG clinical trial number
SWOG-9521
Evaluation of Nuclear p53 in Patients with Epithelial Ovarian Cancer Patients Registered to SWOG-8835, Ancillary
Closed
Phase
Published
Research committees
Gynecologic Cancer
Publication Information Expand/Collapse
2002
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy, and its prognostic role: a Southwest Oncology Group ancillary study
1999
Concordance of pre-and post- chemotherapy p53 immunostaining, and its prognostic significance in epithelial ovarian cancer (EOC) receiving intraperitoneal (IP) consolidation: A Southwest Oncology Group study (SWOG-9521).